Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Clovis Oncology	OrganiGram	Gossamer Bio	Kadmon	Evelo Biosciences
Symbol	NASDAQ:CLVS	NASDAQ:OGI	NASDAQ:GOSS	NASDAQ:KDMN	NASDAQ:EVLO
Price Information
Current Price	$5.29	$2.51	$8.00	$3.61	$9.50
52 Week Range	Hold	Hold	Buy	Buy	Buy
MarketRank™
Overall Score	1.4	1.6	1.7	1.8	1.6
Analysis Score	3.0	4.2	3.5	3.5	3.3
Community Score	2.5	3.0	2.5	3.2	2.3
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	1.7	1.7	1.7
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Hold	Hold	Buy	Buy	Buy
Consensus Price Target	$6.67	$4.41	$23.00	$12.75	$19.80
% Upside from Price Target	26.02% upside	75.75% upside	187.50% upside	253.19% upside	108.42% upside
Trade Information
Market Cap	$589.75 million	$820.14 million	$607.28 million	$620.26 million	$509.19 million
Beta	2.1	0.3	1.34	1.68	1.46
Average Volume	11,110,491	20,954,414	616,819	3,375,953	257,168
Sales & Book Value
Annual Revenue	$143.01 million	$64.61 million	N/A	$5.09 million	N/A
Price / Sales	3.87	11.59	N/A	121.86	N/A
Cashflow	N/A	$0.02 per share	N/A	N/A	N/A
Price / Cash	N/A	101.50	N/A	N/A	N/A
Book Value	($3.17) per share	$1.04 per share	$5.34 per share	$0.95 per share	$1.88 per share
Price / Book	-1.67	2.41	N/A	3.80	N/A
Profitability
Net Income	$-400,420,000.00	$-101,290,000.00	$-180,310,000.00	$-61,370,000.00	$-85,470,000.00
EPS	($7.60)	($0.08)	($3.29)	($0.74)	($2.67)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-230.34%	-207.26%	N/A	-768.36%	N/A
Return on Equity (ROE)	N/A	-10.00%	-64.34%	-85.07%	-159.17%
Return on Assets (ROA)	-57.56%	-7.14%	-46.52%	-46.46%	-88.81%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.17%	0.46%	0.02%	0.59%
Current Ratio	2.33%	2.66%	17.36%	5.76%	6.24%
Quick Ratio	2.14%	3.39%	17.36%	5.76%	6.24%
Ownership Information
Institutional Ownership Percentage	57.83%	10.84%	71.96%	94.78%	84.57%
Insider Ownership Percentage	6.60%	N/A	23.30%	2.95%	7.30%
Miscellaneous
Employees	N/A	619	195	127	90
Shares Outstanding	104.57 million	298.23 million	75.91 million	171.82 million	53.37 million
Next Earnings Date	8/5/2021 (Estimated)	7/20/2021 (Estimated)	8/10/2021 (Estimated)	8/5/2021 (Estimated)	7/29/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Evelo Biosciences (NASDAQ:EVLO) Price Target Cut to $13.00 by Analysts at Morgan Stanley americanbankingnews.com - May 10 at 9:06 AM
	Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down on Analyst Downgrade americanbankingnews.com - May 3 at 12:16 PM
	Evelo Biosciences, Inc. (NASDAQ:EVLO) Short Interest Down 17.9% in April americanbankingnews.com - May 3 at 7:18 AM
	Evelo Biosciences (NASDAQ:EVLO) Posts Earnings Results, Misses Expectations By $0.04 EPS americanbankingnews.com - April 30 at 3:58 PM
	Evelo Biosciences (NASDAQ:EVLO) Trading Up 5.2% americanbankingnews.com - April 30 at 2:44 PM
	Evelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call Transcript finance.yahoo.com - April 29 at 7:02 PM
	Evelo Biosciences, Inc.: Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights finanznachrichten.de - April 29 at 9:01 AM
	Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights finance.yahoo.com - April 29 at 9:00 AM
	Evelo Biosciences (NASDAQ:EVLO) Trading Down 3.9% americanbankingnews.com - April 28 at 1:58 PM
	Evelo Biosciences, Inc. (NASDAQ:EVLO) Given Consensus Recommendation of "Buy" by Brokerages americanbankingnews.com - April 27 at 4:40 AM
	Zacks: Analysts Anticipate Evelo Biosciences, Inc. (NASDAQ:EVLO) Will Post Earnings of -$0.53 Per Share americanbankingnews.com - April 26 at 10:22 PM
	Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $11.16 americanbankingnews.com - April 23 at 11:37 AM
	Evelo Biosciences (EVLO) to Release Earnings on Thursday americanbankingnews.com - April 23 at 8:38 AM
	Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021 finance.yahoo.com - April 22 at 7:32 AM
	Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis finance.yahoo.com - April 20 at 6:12 PM
	Evelo Biosciences (NASDAQ:EVLO) Shares Down 7.2% americanbankingnews.com - April 20 at 1:40 PM
	Are Institutions Heavily Invested In Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Shares? finance.yahoo.com - April 19 at 12:06 PM
	Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down to $11.56 americanbankingnews.com - April 19 at 12:02 PM
	Evelo Biosciences (NASDAQ:EVLO) Upgraded at Jefferies Financial Group americanbankingnews.com - April 19 at 8:46 AM
	Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. apnews.com - April 16 at 10:06 AM
	Evelo Biosciences (NASDAQ:EVLO) Trading Up 6.9% americanbankingnews.com - April 15 at 11:37 AM
	Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors finance.yahoo.com - April 15 at 7:52 AM
	Evelo Biosciences, Inc. (EVLO) investors to reap big returns again marketingsentinel.com - April 13 at 9:48 AM
	Market Analysts see Evelo Biosciences Inc. [EVLO] gaining to $18. Time to buy? dbtnews.com - April 13 at 9:48 AM
	Thinking about buying stock in Nuance Communications, GameStop, Evelo Biosciences, Progenity, or Fortress Biotech? marketwatch.com - April 12 at 1:28 PM

Date	Company	Brokerage	Action
5/5/2021	Clovis Oncology	HC Wainwright	Lower Price Target
11/6/2020	Clovis Oncology	SVB Leerink	Lower Price Target
11/5/2020	Clovis Oncology	Piper Sandler	Lower Price Target
11/1/2020	Clovis Oncology	JPMorgan Chase & Co.	Reiterated Rating
4/20/2020	Clovis Oncology	Royal Bank of Canada	Reiterated Rating
4/19/2020	Clovis Oncology	Bank of America	Downgrade
11/27/2019	Clovis Oncology	Evercore ISI	Downgrade
4/20/2021	OrganiGram	CIBC	Reiterated Rating
4/15/2021	OrganiGram	Stifel Nicolaus	Boost Price Target
4/14/2021	OrganiGram	Raymond James	Lower Price Target
4/14/2021	OrganiGram	Canaccord Genuity	Boost Price Target
4/13/2021	OrganiGram	Alliance Global Partners	Lower Price Target
4/8/2021	OrganiGram	BMO Capital Markets	Upgrade
3/11/2021	OrganiGram	Cantor Fitzgerald	Reiterated Rating
8/10/2020	OrganiGram	Jefferies Financial Group	Reiterated Rating
10/16/2020	Gossamer Bio	Barclays	Lower Price Target
10/30/2019	Gossamer Bio	Berenberg Bank	Initiated Coverage
11/11/2020	Kadmon	Mizuho	Initiated Coverage
9/22/2020	Kadmon	Oppenheimer	Reiterated Rating
1/10/2020	Kadmon	Nomura Securities	Initiated Coverage
2/26/2019	Kadmon	Citigroup	Upgrade
10/17/2018	Kadmon	WBB Securities	Upgrade
5/10/2021	Evelo Biosciences	Morgan Stanley	Lower Price Target
3/12/2021	Evelo Biosciences	Chardan Capital	Boost Price Target
1/25/2021	Evelo Biosciences	JMP Securities	Boost Price Target
2/14/2020	Evelo Biosciences	Cowen	Reiterated Rating

(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources